These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 30433823)
1. Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Deitelzweig S; Guo JD; Hlavacek P; Lin J; Wygant G; Rosenblatt L; Gupta A; Pan X; Mardekian J; Lingohr-Smith M; Menges B; Marshall A; Nadkarni A Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):261S-268S. PubMed ID: 30433823 [TBL] [Abstract][Full Text] [Related]
2. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department. Deitelzweig S; Hlavacek P; Mardekian J; Rosenblatt L; Russ C; Tuell K; Lingohr-Smith M; Lin J; Guo JD Hosp Pract (1995); 2020 Feb; 48(1):41-48. PubMed ID: 31976776 [No Abstract] [Full Text] [Related]
3. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database. Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277 [TBL] [Abstract][Full Text] [Related]
4. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467 [No Abstract] [Full Text] [Related]
5. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879 [TBL] [Abstract][Full Text] [Related]
6. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644 [TBL] [Abstract][Full Text] [Related]
7. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. Xie L; Vo L; Keshishian A; Price K; Singh P; Mardekian J; Bruno A; Baser O; Kim J; Tan W; Trocio J J Med Econ; 2016 Aug; 19(8):769-76. PubMed ID: 27028360 [TBL] [Abstract][Full Text] [Related]
8. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753 [TBL] [Abstract][Full Text] [Related]
9. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446 [TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557 [TBL] [Abstract][Full Text] [Related]
11. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US. Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383 [No Abstract] [Full Text] [Related]
12. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139 [TBL] [Abstract][Full Text] [Related]
13. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179 [TBL] [Abstract][Full Text] [Related]
14. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203 [TBL] [Abstract][Full Text] [Related]
15. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice. Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780 [TBL] [Abstract][Full Text] [Related]
17. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status. Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X Adv Ther; 2021 Nov; 38(11):5519-5533. PubMed ID: 34570310 [TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190 [TBL] [Abstract][Full Text] [Related]
20. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]